Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.
Prostate Cancer Screenings on the Decline with Concerns Surrounding COVID-19: What Men Should Know
Feb. 22, 2021
FacebookTwitterEmail
(BPT) - In the early part of the COVID-19 pandemic, many areas of the country banned nonessential medical procedures in an effort to slow the spread of the disease. As a result, many physicians saw fewer patients for routine medical care, such as physical exams and screenings. A recent survey by The Physicians Foundation polled 3,513 physicians and found 41% saw volume decreases of 26% or more in their practices.
The impact on cancer screenings was even more profound. For example, screenings for prostate cancer one of the most commonly diagnosed cancers in men in the United States dropped by 56% by the peak of the pandemic in April according to a recent study published in